|
|
Genentech, Eli Lilly and Versant Ventures on �Identify, Strike, & Manage�
Strategies for a Successful Partnership
|
|
|
A Panel & Networking Event
Thursday November 9, 2006
Agenda
� 3:00-3:30 PM Networking & Registration
� 3:30-5:00 PM Experts Panel
� 5:00-6:30 PM Wine & Cheese Networking Reception
Any successful alliance revolves around these three words "Identify, Strike, & Manage".
During this discussion, our Expert Panel, with a specific emphasis on the process Genentech and Eli Lilly engage in for partnerships, will speak on:
1. Identifying the Partner - Initially, the company must identify who the right partners will be for their type of organization and make certain that there is strategic alignment with the proposed partner.
2. Striking the Deal - Once the partner or potential partners have been determined, the efforts then go into striking the deal; ensuring success in this stage includes securing appropriate commitments, aligning incentives and clear communication of expectations, all as part of striking the right deal terms.
3. Alliance Management - The last and very crucial phase is, of course, managing the alliance and the relationship; signing the deal is the start of the relationship and its management, not an endpoint.
The roundtable discussion format is interactive and informal and intended to be a conversation more than a presentation. So bring your questions with you!
Panelists:
Camille D. Samuels, Managing Director, Versant Ventures ~ Click Here for Bio
James Chubb, Partner, ProPharma Partners ~ Click Here for Bio
Anton Gueth, Senior Consultant, Vantage Partners, Former Eli Lilly Director of Alliance Management ~ Click Here for Bio
Robert Cohen, Senior Director-Oncology Strategy, Business Development, Genentech ~ Click Here for Bio
Peter Condon, Senior Manager, Business Development, Genentech ~ Click Here for Bio
Moderator:
Ron Star, Director, Howard Rice Nemerovski Canady Falk & Rabkin ~ Click Here for Bio
This event is sponsored by:
Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to rapidly, repeatedly, and safely control bio-molecular interactions. The Company currently holds 13 US/5 foreign patents covering multiple applications of PCT, including genomic and proteomic sample preparation, pathogen inactivation, enzyme control, immunodiagnostics, and protein purification. PBI developed and markets the PCT Sample Preparation System, an excellent tool for the extraction of DNA/RNA/proteins/small molecules from a variety of animal/plant/microbe/human cells and tissues.
Moderator & Panelists' Bios:
Ron Star, Director, Howard Rice Nemerovski Canady Falk & Rabkin
Mr. Star is a director of the firm focusing on securities law, financings, venture capital, intellectual property and mergers and acquisitions. He works closely with start-up and private companies on issues related to equity and financings, intellectual property matters, the structuring of executive compensation (including stock arrangements), strategic ventures, acquisitions and management buy-outs. He was recognized as a Northern California Super Lawyer in 2004 and 2005 by Law & Politics, which published a list of the winners in San Francisco magazine.
Mr. Star's engagements run the gamut from representing start-up companies in formation to representing major multinational companies in strategic investments. His particular industry specialties include computer software and hardware, semiconductors, information services businesses, internet and multimedia companies, medical technology, food related companies, retail operations and financial services companies.
Mr. Star is a lecturer at the Haas School of Business at the University of California at Berkeley, and teaches a second year MBA course on entrepreneurship. He is a guest lecturer at Stanford University's Graduate School of Business. He also has been a member of the faculty of the San Francisco State Multimedia Studies Program, and is a frequent lecturer on venture capital transactions, acquisitions, computer law, multimedia, strategic partnerships, employment matters and closely held businesses.
His representative clients include Transmeta Corporation, Tower Semiconductor, Ltd., Maxager Technology, Inc., Artemis Medical Inc., Allegis Capital, Sofinnova Ventures, Rheodyne, L.P., Reiter Affiliated Companies, Vocera Communications, Navis Corporation and Steeleye Technology, Inc. Mr. Star has a J.D., Harvard Law School (magna cum laude; editor, Harvard Law Review, editor-at-large, Harvard Environmental Law Review, a M.B.A., Harvard Business School (with distinction), and a B.A., Harvard University (magna cum laude).
Mr. Star is a lecturer at the Haas School of Business at the University of California at Berkeley, and teaches a second year MBA course on entrepreneurship. He is a guest lecturer at Stanford University's Graduate School of Business. He also has been a member of the faculty of the San Francisco State Multimedia Studies Program, and is a frequent lecturer on venture capital transactions, acquisitions, computer law, multimedia, strategic partnerships, employment matters and closely held businesses.
Camille D. Samuels, Managing Director, Versant Ventures
Camille Samuels specializes in biotechnology investing at Versant. Camille joined Versant in early 2000, shortly after its formation.
Prior to Versant, Camille was responsible for business development at Tularik, Inc. (subsequently acquired by Amgen) where she in-licensed two of the company's clinical-stage products and led Tularik�s Technology Acquisition Group. Before Tularik, Camille worked in business development/strategic planning at Genzyme and Millennium Predictive Medicine, and as a management consultant to healthcare and biotech companies at LEK Consulting.
Camille currently serves as a board member of the following private companies: Achaogen, Kythera, Novacardia, as well as Novacea (NOVC), a public company. Camille was previously a board observer at several companies, including 5 AM, Alexza (public), Genomic Health (public) and Syrrx (sold) as well as Pathwork Diagnostics (formerly Predicant Biosciences).
Camille earned her Bachelor's degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Camille a Henry Crown Fellow.
James Chubb, Partner, ProPharma Partners
James Chubb, Ph.D. is broadly experienced in operational management, strategy and financing of biopharmaceutical companies, as well as possessing extensive pharmaceutical product development experience.
As a senior executive at Glaxo with more than 12 years of experience, Dr. Chubb was responsible for directing the filing of more than 15 NDAs and ANDs for anti-bacterial and anti-fungal drugs, beta agonist bronchodilators and inhaled steroids for asthma, topical steroids for dermatological indications and serotonin antagonists for cancer induced nausea and vomiting. As President and Chief Executive of Triplex Pharmaceuticals and its successor, Aronex Pharmaceuticals, for 8 years, Dr Chubb raised over $65 million in financing, and established several corporate partnerships. He built a strong management team and over saw advancement of three cancer drugs and an antifungal into clinical trials. Dr. Chubb was subsequently founder and principal of ProPharma International Partners, Inc, a consulting and advisory service company to biotechnology companies, with locations in the San Francisco Bay area and London, UK.
Dr. Chubb received his Ph.D. in Pharmacology from the University of Arizona College of Medicine and completed a cardiovascular research fellowship at Michigan State University.
Anton Gueth, Senior Consultant, Vantage Partners
Anton Gueth is a senior consultant with Vantage Partners. He is a recognized expert on alliance management and strategy, specializing in the pharmaceutical industry. Mr. Gueth has held numerous positions in management, sales, marketing, and finance in a variety of countries. He previously served as the Director of Alliance Management at Eli Lilly and Company, where he led Lilly�s efforts to become the pharmaceutical partner of choice. Mr. Gueth also serves on the Board of Directors for Antares Pharma.
As a practitioner, author, and lecturer on the topic of Alliance Management, Mr. Gueth has addressed his work to a variety of audiences in the United States, Europe, Asia and Latin America. His articles can be found in In Vivo: The Business & Medicine Report, Pharmaceutical Technology, and The Ernst & Young Biotechnology Report. In addition, he is a contributing author to the recent book, Mastering Alliance Strategy � A Comprehensive Guide to Design, Management, and Organization by James Bamford, Benjamin Gomes-Casseres, and Michael S. Robinson.
A native of Germany, Mr. Gueth has lived and worked all over the world, including Europe, the United States, Africa, and the Middle East. He holds a Masters Degree in Agricultural Economics from Justus-Liebig University, and a Masters Degree in Public Affairs from Indiana University, Bloomington.
Robert Cohen, Senior Director-Oncology Strategy, Business Development, Genentech
Bob Cohen has worked at Genentech in a variety of capacities since 1994. Bob is a board certified hematologist/oncologist who completed his training at UCSF before joining the faculty there in 1989. During this time he did basic research on mechanisms of metastasis. His clinical specialty was the care of leukemia patients and patients receiving bone marrow transplants. He is the author of over 30 scientific publications and holds 3 patents. Bob initially came to Research upon joining Genentech. In 1996 he became the project team leader for Herceptin and led that project through Phase III completion and registration. He also led the Genentech team that co-developed the companion diagnostic HercepTest. In 2004, Bob joined Business Development as a senior director in the newly formed Oncology licensing group, where he currently focuses on identifying new in-licensing opportunities. Bob has a long history of successful work with business development, having played important roles on both the Rituxan and Tarceva in-licensing deals, among others. In addition to his work at Genentech, Bob has served on a number of external scientific advisory boards, including several NIH committees and the scientific advisory board of ABC2, a brain cancer research and advocacy organization.
Peter Condon, Senior Manager, Business Development, Genentech
Peter Condon has worked at Genentech since 2000. Peter holds an MBA from the Wharton Business School, and has an undergraduate degree in economics from Harvard University. At Genentech, Peter began his career in the Market Development group where he conducted the launch planning efforts for Xolair and led the market research and forecasting activities for Genentech's specialty therapeutics group.
In 2003, Peter joined Business Development in the Oncology licensing group and has successfully completed a number of research and product licensing transactions. Prior to Genentech, Peter worked as a consultant to health care companies in the Health Care Group at Booz Allen & Hamilton.
|
|
|
|
